Polycystic ovarian syndrome and its associated endocrine abnormalities comprise one of the most common metabolic spectrum disorders within the human race. Because of the variance in phenotypic expression among individuals and within family lineages, attention has been turned to genetic and epigenetic changes in which the root cause of the disorder may lie. Further understanding of DNA/histone methylation and microRNA patterns may help to improve the accuracy of diagnosis and lead to future treatment options.

No abstract

SARS CoV-2, otherwise known as Corona virus 2019 (COVID-19) has left >300,000 dead without a definitive cure in sight. Significant research has been conducted regarding the use of currently available pharmacotherapies and multiple clinical trials are underway to bring new treatments to market. While supportive treatment remains the standard of care, additional therapeutic regimens including antivirals, monoclonal antibodies, antibiotics, anti-inflammatories, immunoenhancers, vitamins, systemic steroids, inhalants, anticoagulants, and convalescent plasma are showing promise.